About Transmembrane protein 53
Transmembrane protein 53 (TMEM53) is a protein
from Homo sapiens identified by UniProt accession
Q6P2H8, 277 residues long.
MolForge cross-references it against 0 known binders and
237 disease associations.
Target properties
| Protein name | Transmembrane protein 53 |
| UniProt accession | Q6P2H8 |
| Gene | TMEM53 |
| Organism | Homo sapiens |
| Length | 277 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (237)
Diseases linked to this target (Open Targets).
- craniotubular dysplasia, Ikegawa type · score 0.52
- leukodystrophy, hypomyelinating, 23, with ataxia, deafness, liver dysfunction, and dilated cardiomyopathy · score 0.42
- brachydactylous dwarfism, Mseleni type · score 0.10
- X-linked non-syndromic intellectual disability · score 0.09
- Bartter syndrome · score 0.09
- SHOX-related short stature · score 0.09
- heart rate response to recovery post exercise · score 0.09
- heart rate response to exercise · score 0.09
- chromosome 22q11.2 deletion syndrome, distal · score 0.07
- Hyaluronidase deficiency · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q6P2H8-F1 | alphafold | PREDICTED | 89.43 | — |
Amino-acid sequence (277 residues)
MASAELDYTI EIPDQPCWSQ KNSPSPGGKE AETRQPVVIL LGWGGCKDKN LAKYSAIYHK RGCIVIRYTA PWHMVFFSES LGIPSLRVLA QKLLELLFDY EIEKEPLLFH VFSNGGVMLY RYVLELLQTR RFCRLRVVGT IFDSAPGDSN LVGALRALAA ILERRAAMLR LLLLVAFALV VVLFHVLLAP ITALFHTHFY DRLQDAGSRW PELYLYSRAD EVVLARDIER MVEARLARRV LARSVDFVSS AHVSHLRDYP TYYTSLCVDF MRNCVRC
Explore Transmembrane protein 53 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets